Table 4.

Multivariate Cox regression analysis of variables associated with the risk of progression in the 138 patients with PanNET treated with TEM or TEM-CAP

	HR (95% CI)	p value
TEM-CAP (vs. TEM alone)	0.65 (0.37–1.12)	0.12
Hormonal syndrome (vs. absence)	1.89 (1.09–3.29)	0.02
Ki–67 index (each additional 1%)	1.03 (1.01–1.06)	0.003
WHO PS-1 or PS-2 (vs. WHO PS-0)	2.27 (1.40–3.66)	0.001
Extrahepatic metastases (vs. absence)	1.88 (1.20–2.93)	0.006
Delay to diagnosis (each additional month)	1.00 (0.99–1.01)	0.23
Primary tumor surgery (vs. absence)	0.57 (0.36–0.90)	0.02
Previous chemotherapy administration (vs. absence)	1.79 (1.08–2.96)	0.03
Previous somatostatin analog administration (vs. absence)	1.39 (0.83–2.34)	0.21

Bold type denotes significance. PanNET, pancreatic neuroendocrine tumor; TEM, temozolomide; CAP, capecitabine; PS, performance status.